cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.4632869
title: Raw Data for the article: Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency

description: <strong>ackground: </strong>Autoimmune pancreatitis (AIP) is a rare, and relatively new, form of chronic pancreatitis. The management of AIP can vary considerably among different centres in daily clinical practice. <strong>Objectives: </strong>The aim of this study is to present a picture of epidemiological, clinical characteristics, outcomes, and the real-life practice in terms of management in several academic and non-academic centres in Italy. <strong>Methods: </strong>Data on the clinical presentation, diagnostic work-up, treatments, frequency of relapses, and long-term outcomes were retrospectively collected in a cohort of AIP patients diagnosed at 14 centres in Italy. <strong>Results: </strong>One hundred and six patients were classified as type 1 AIP, 48 as type 2 AIP, and 19 as not otherwise specified. Epidemiological, clinical, radiological, and serological characteristics, and relapses were similar to those previously reported for different types of AIP. Endoscopic cytohistology was available in 46.2% of cases, and diagnostic for AIP in only 35.2%. Steroid trial to aid diagnosis was administered in 43.3% cases, and effective in 93.3%. Steroid therapy was used in 70.5% of cases, and effective in 92.6% of patients. Maintenance therapy with low dose of steroid (MST) was prescribed in 25.4% of cases at a mean dose of 5 (±1.4) mg/die, and median time of MST was 60 days. Immunosuppressive drugs were rarely used (10.9%), and rituximab in 1.7%. Faecal elastase-1 was evaluated in only 31.2% of patients, and was pathological in 59.2%. <strong>Conclusions: </strong>In this cohort of AIP patients, diagnosis and classification for subtype was frequently possible, confirming the different characteristics of AIP1 and AIP2 previously reported. Nevertheless, we observed a low use of histology and steroid trial for a diagnosis of AIP. Steroid treatment was the most used therapy in our cohort. Immunosuppressants and rituximab were rarely used. The evaluation of exocrine pancreatic insufficiency is underemployed considering its high prevalence.
DOI: 10.5281/zenodo.4632868
title: Raw Data for the article: Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency

description: <strong>ackground: </strong>Autoimmune pancreatitis (AIP) is a rare, and relatively new, form of chronic pancreatitis. The management of AIP can vary considerably among different centres in daily clinical practice. <strong>Objectives: </strong>The aim of this study is to present a picture of epidemiological, clinical characteristics, outcomes, and the real-life practice in terms of management in several academic and non-academic centres in Italy. <strong>Methods: </strong>Data on the clinical presentation, diagnostic work-up, treatments, frequency of relapses, and long-term outcomes were retrospectively collected in a cohort of AIP patients diagnosed at 14 centres in Italy. <strong>Results: </strong>One hundred and six patients were classified as type 1 AIP, 48 as type 2 AIP, and 19 as not otherwise specified. Epidemiological, clinical, radiological, and serological characteristics, and relapses were similar to those previously reported for different types of AIP. Endoscopic cytohistology was available in 46.2% of cases, and diagnostic for AIP in only 35.2%. Steroid trial to aid diagnosis was administered in 43.3% cases, and effective in 93.3%. Steroid therapy was used in 70.5% of cases, and effective in 92.6% of patients. Maintenance therapy with low dose of steroid (MST) was prescribed in 25.4% of cases at a mean dose of 5 (±1.4) mg/die, and median time of MST was 60 days. Immunosuppressive drugs were rarely used (10.9%), and rituximab in 1.7%. Faecal elastase-1 was evaluated in only 31.2% of patients, and was pathological in 59.2%. <strong>Conclusions: </strong>In this cohort of AIP patients, diagnosis and classification for subtype was frequently possible, confirming the different characteristics of AIP1 and AIP2 previously reported. Nevertheless, we observed a low use of histology and steroid trial for a diagnosis of AIP. Steroid treatment was the most used therapy in our cohort. Immunosuppressants and rituximab were rarely used. The evaluation of exocrine pancreatic insufficiency is underemployed considering its high prevalence.
DOI: 10.5281/zenodo.6188138
title: The Hume Vocal Burst Competition Dataset (H-VB) | Raw Data [A-VB: updated 02.20.222]

description: This package includes the raw data for a subset of The Hume Vocal Burst Database (H-VB). This dataset contains <strong>59,201 audio recordings of vocal bursts from 1,702 speakers</strong>, from 4 cultures, the <strong>U.S.A, South Africa, China, </strong>and<strong> Venezuela</strong>, ranging in age from <strong>20 to 39.5 years old</strong>. The total duration of data in this version of <strong>H-VB is 36 Hours </strong> (Mean: 02.23 sec). A subset of 10 emotional intensity labels is also available. Data has been partitioned into equal training, validation, and test sets, and the test set is blind. <strong>Emotion Labels: </strong><br> <em>Awe, Excitement, Amusement, Awkwardness, Fear, Horror, Distress, Triumph, Sadness, Surprise, Valence, Arousal</em> For further questions about the data contact: <strong>competitions@hume.ai</strong>
DOI: 10.5281/zenodo.4632914
title: Raw Data for the article: OCCUPATIONAL RADIATION DOSE PERFORMING HEPATOBILIARY MINIMALLY INVASIVE PROCEDURES IN CHILDREN WEIGHING LESS THAN 20 kg

description: Our objective is to retrospectively evaluate the effective dose (E) of operators performing pediatric Hepatobiliary Minimally Invasive Procedures (HMIP). Between October 2015 and December 2017, 58 consecutive HMIP were performed on 26 children weighing less than 20 kg (mean 12.3 kg, median 13 kg, range 2.4-20 kg). About 31 vascular procedures (n = 9 hepatic venograms with/without stenting; n = 9 retrograde wedge portography; n = 8 transhepatic portography with angioplasty and/or stenting and n = 5 hepatic arteriography/embolization) and 27 non-vascular procedures (n = 6 percutaneous transhepatic biliary drainage (PTBD); n = 3 bilioplasty; n = 15 biliary catheter change and n = 3 cholangiogram) were performed. Electronic personal dosimeters were used to measure radiation doses to the interventional radiologist, radiographer and anesthesia nurse. The results shows the highest mean effective dose: interventional radiologist's in PTBD (1.18 μSv); radiographer's in hepatic veins phlebography with/without stenting (0.25 μSv) and nurse's in hepatic arteriography/embolization (0.26 μSv). Operators' E can vary depending on the complexity of procedure performed and the position of the operators within the angiosuite.
DOI: 10.5281/zenodo.4632913
title: Raw Data for the article: OCCUPATIONAL RADIATION DOSE PERFORMING HEPATOBILIARY MINIMALLY INVASIVE PROCEDURES IN CHILDREN WEIGHING LESS THAN 20 kg

description: Our objective is to retrospectively evaluate the effective dose (E) of operators performing pediatric Hepatobiliary Minimally Invasive Procedures (HMIP). Between October 2015 and December 2017, 58 consecutive HMIP were performed on 26 children weighing less than 20 kg (mean 12.3 kg, median 13 kg, range 2.4-20 kg). About 31 vascular procedures (n = 9 hepatic venograms with/without stenting; n = 9 retrograde wedge portography; n = 8 transhepatic portography with angioplasty and/or stenting and n = 5 hepatic arteriography/embolization) and 27 non-vascular procedures (n = 6 percutaneous transhepatic biliary drainage (PTBD); n = 3 bilioplasty; n = 15 biliary catheter change and n = 3 cholangiogram) were performed. Electronic personal dosimeters were used to measure radiation doses to the interventional radiologist, radiographer and anesthesia nurse. The results shows the highest mean effective dose: interventional radiologist's in PTBD (1.18 μSv); radiographer's in hepatic veins phlebography with/without stenting (0.25 μSv) and nurse's in hepatic arteriography/embolization (0.26 μSv). Operators' E can vary depending on the complexity of procedure performed and the position of the operators within the angiosuite.
DOI: 10.6084/m9.figshare.19228416.v1
title: Small RNA viruses - Nanopore sequencing data

description: Sequencing data of six human pathogen RNA viruses
DOI: 10.5517/ccdc.csd.cc286f97
title: CCDC 2091548: Experimental Crystal Structure Determination

description: Related Article: Yuri M. Shafran, Aqeel A. Hussein, Nikolai A. Beliaev, Vadim A. Shevyrin, Sergey Shityakov, Tetyana V. Beryozkina, Vasiliy A. Bakulev|2022|ACS Omega|7|5008|doi:10.1021/acsomega.1c05898
DOI: 10.5517/ccdc.csd.cc286ffc
title: CCDC 2091552: Experimental Crystal Structure Determination

description: Related Article: Yuri M. Shafran, Aqeel A. Hussein, Nikolai A. Beliaev, Vadim A. Shevyrin, Sergey Shityakov, Tetyana V. Beryozkina, Vasiliy A. Bakulev|2022|ACS Omega|7|5008|doi:10.1021/acsomega.1c05898
DOI: 10.5517/ccdc.csd.cc28khmz
title: CCDC 2102191: Experimental Crystal Structure Determination

description: Related Article: Muhammad Ashfaq, Muhammad Nawaz Tahir, Shabbir Muhammad, Khurram Shahzad Munawar, Saqib Ali, Gulzar Ahmed, Abdullah G. Al-Sehemi, Saleh S. Alarfaji, Muhammad Ehtisham Ibraheem Khan|2022|ACS Omega|7|5217|doi:10.1021/acsomega.1c06325
DOI: 10.5517/ccdc.csd.cc28khn0
title: CCDC 2102192: Experimental Crystal Structure Determination

description: Related Article: Muhammad Ashfaq, Muhammad Nawaz Tahir, Shabbir Muhammad, Khurram Shahzad Munawar, Saqib Ali, Gulzar Ahmed, Abdullah G. Al-Sehemi, Saleh S. Alarfaji, Muhammad Ehtisham Ibraheem Khan|2022|ACS Omega|7|5217|doi:10.1021/acsomega.1c06325
DOI: 10.5517/ccdc.csd.cc29fbkn
title: CCDC 2127981: Experimental Crystal Structure Determination

description: Related Article: Sungho V. Park, Amanda R. Corcos, Alexander N. Jambor, Tzuhsiung Yang, John F. Berry|2022|J.Am.Chem.Soc.|144|3259|doi:10.1021/jacs.1c13396
DOI: 10.5517/ccdc.csd.cc29fbrv
title: CCDC 2127987: Experimental Crystal Structure Determination

description: Related Article: Xiuling Zhang, Junna Fu, Guangyin Wang, Hui Hu, Da-Shuai Zhang, Yong-Zheng Zhang, Yan-Kai Zhang, Zhen-Wei Zhang, Wen-Feng Zhou, Ting-Ting Li, Dongjun Lv, Longlong Geng|2022|J.Solid State Chem.|309|122964|doi:10.1016/j.jssc.2022.122964
DOI: 10.5517/ccdc.csd.cc29fbsw
title: CCDC 2127988: Experimental Crystal Structure Determination

description: Related Article: Xiuling Zhang, Junna Fu, Guangyin Wang, Hui Hu, Da-Shuai Zhang, Yong-Zheng Zhang, Yan-Kai Zhang, Zhen-Wei Zhang, Wen-Feng Zhou, Ting-Ting Li, Dongjun Lv, Longlong Geng|2022|J.Solid State Chem.|309|122964|doi:10.1016/j.jssc.2022.122964
DOI: 10.5517/ccdc.csd.cc29fbtx
title: CCDC 2127989: Experimental Crystal Structure Determination

description: Related Article: Xiuling Zhang, Junna Fu, Guangyin Wang, Hui Hu, Da-Shuai Zhang, Yong-Zheng Zhang, Yan-Kai Zhang, Zhen-Wei Zhang, Wen-Feng Zhou, Ting-Ting Li, Dongjun Lv, Longlong Geng|2022|J.Solid State Chem.|309|122964|doi:10.1016/j.jssc.2022.122964
DOI: 10.5517/ccdc.csd.cc29fbvy
title: CCDC 2127990: Experimental Crystal Structure Determination

description: Related Article: Xiuling Zhang, Junna Fu, Guangyin Wang, Hui Hu, Da-Shuai Zhang, Yong-Zheng Zhang, Yan-Kai Zhang, Zhen-Wei Zhang, Wen-Feng Zhou, Ting-Ting Li, Dongjun Lv, Longlong Geng|2022|J.Solid State Chem.|309|122964|doi:10.1016/j.jssc.2022.122964
DOI: 10.5281/zenodo.4632964
title: Raw Data for the article: Extracorporeal life support for phaeochromocytoma-induced cardiogenic shock: a systematic review

description: <strong>Introduction: </strong>Phaeochromocytoma is a catecholamine-secreting tumour associated with clinical presentation ranging from paroxysmal hypertension to intractable cardiogenic shock. Extracorporeal life support, in veno-arterial mode, application in refractory acute heart dysfunction is sharply increasing worldwide. However, its clinical utility in phaeochromocytoma-induced cardiogenic shock remains still unclear. <strong>Methods: </strong>A systematic review of published reports was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement. Searches were accomplished on PubMed, Embase and Google Scholar to identify articles describing the use of extracorporeal life support in the setting of phaeochromocytoma-induced cardiogenic shock (PROSPERO: CRD42019125225). <strong>Results: </strong>Thirty-five reports, including 62 patients supported with extracorporeal life support because of intractable phaeochromocytoma crisis, were included for the analysis. Almost all the subjects underwent peripheral cannulation for extracorporeal life support. The median duration of the mechanical circulatory support was 5 days, and most of the patients recovered normal myocardial function (left ventricular ejection fraction ⩾50%). In-hospital survival was 87%. Phaeochromocytoma was removed surgically during extracorporeal life support in 10 patients (16%), while in the remaining after haemodynamic stabilization and weaning from the mechanical support. <strong>Conclusion: </strong>Successful management of phaeochromocytoma-induced cardiogenic shock depends on prompt recognition and immediate treatment of shock. In this scenario, extracorporeal life support may play a significant role allowing cardiac and end-organ recovery and giving time for accurate diagnosis and specific treatment.
DOI: 10.5281/zenodo.4632963
title: Raw Data for the article: Extracorporeal life support for phaeochromocytoma-induced cardiogenic shock: a systematic review

description: <strong>Introduction: </strong>Phaeochromocytoma is a catecholamine-secreting tumour associated with clinical presentation ranging from paroxysmal hypertension to intractable cardiogenic shock. Extracorporeal life support, in veno-arterial mode, application in refractory acute heart dysfunction is sharply increasing worldwide. However, its clinical utility in phaeochromocytoma-induced cardiogenic shock remains still unclear. <strong>Methods: </strong>A systematic review of published reports was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement. Searches were accomplished on PubMed, Embase and Google Scholar to identify articles describing the use of extracorporeal life support in the setting of phaeochromocytoma-induced cardiogenic shock (PROSPERO: CRD42019125225). <strong>Results: </strong>Thirty-five reports, including 62 patients supported with extracorporeal life support because of intractable phaeochromocytoma crisis, were included for the analysis. Almost all the subjects underwent peripheral cannulation for extracorporeal life support. The median duration of the mechanical circulatory support was 5 days, and most of the patients recovered normal myocardial function (left ventricular ejection fraction ⩾50%). In-hospital survival was 87%. Phaeochromocytoma was removed surgically during extracorporeal life support in 10 patients (16%), while in the remaining after haemodynamic stabilization and weaning from the mechanical support. <strong>Conclusion: </strong>Successful management of phaeochromocytoma-induced cardiogenic shock depends on prompt recognition and immediate treatment of shock. In this scenario, extracorporeal life support may play a significant role allowing cardiac and end-organ recovery and giving time for accurate diagnosis and specific treatment.
DOI: 10.5281/zenodo.4633065
title: Raw Data for the article: Transaortic or Pulmonary Artery Drainage for Left Ventricular Unloading in Venoarterial Extracorporeal Life Support: A Porcine Cardiogenic Shock Model

description: The peripheral venoarterial extracorporeal life support (V-A ECLS) in cardiogenic shock (CS) may lead to LV overload. The transaortic suction device (Impella, ABIOMED Inc., Danvers, MA) was compared to the pulmonary artery (PA) drainage, for LV unloading efficacy during V-A ECLS in a porcine cardiogenic shock model. A dedicated CS model included 12 swine (21 ± 1.8-week-old and weighing 54.3 ± 4.6 kg) supported with V-A ECLS and randomized to Impella or PA-related LV drainage. LV unloading and end-organ perfusion were evaluated through the PA catheter and LV pressure/volume analysis. The LV end-diastolic volume sharply dropped with Impella (143.6 ± 67.4 vs 123 ± 75.7 mL) compared to a slight decrease in the PA cannula group (134.1 ± 39.9 vs 130.1 ± 34.7 mL), resulting in an overall stroke work and pressure-volume area reductions with both techniques. However, stroke work reduction was more significant in the Impella group (V-A ECLS 3998.8 ± 2027.6 vs V-A ECLS + Impella 1796.9 ± 1033.9 mm Hg × mL, P = 0.016), leading to a more consistent pressure-volume area reduction (Impella reduction 34.7% vs PA cannula reduction 9.7%) In terms of end organ perfusion, central and mixed O<sub>2</sub> saturation improved with V-A ECLS, and subsequently, remaining unchanged with either Impella or PA cannula as unloading strategy (SVmO2: Impella 86.0 ± 5.8 vs 87.8 ± 5.8; PA cannula 82.5 ± 10.7 vs 82.5 ± 11.3 %). Transaortic suction and PA drainage provided effective LV unloading during V-A ECLS while maintaining adequate end-organ perfusion. Impella provides a greater LV unloading effect and reduces more effectively the total LV stroke work.
DOI: 10.5281/zenodo.4633064
title: Raw Data for the article: Transaortic or Pulmonary Artery Drainage for Left Ventricular Unloading in Venoarterial Extracorporeal Life Support: A Porcine Cardiogenic Shock Model

description: The peripheral venoarterial extracorporeal life support (V-A ECLS) in cardiogenic shock (CS) may lead to LV overload. The transaortic suction device (Impella, ABIOMED Inc., Danvers, MA) was compared to the pulmonary artery (PA) drainage, for LV unloading efficacy during V-A ECLS in a porcine cardiogenic shock model. A dedicated CS model included 12 swine (21 ± 1.8-week-old and weighing 54.3 ± 4.6 kg) supported with V-A ECLS and randomized to Impella or PA-related LV drainage. LV unloading and end-organ perfusion were evaluated through the PA catheter and LV pressure/volume analysis. The LV end-diastolic volume sharply dropped with Impella (143.6 ± 67.4 vs 123 ± 75.7 mL) compared to a slight decrease in the PA cannula group (134.1 ± 39.9 vs 130.1 ± 34.7 mL), resulting in an overall stroke work and pressure-volume area reductions with both techniques. However, stroke work reduction was more significant in the Impella group (V-A ECLS 3998.8 ± 2027.6 vs V-A ECLS + Impella 1796.9 ± 1033.9 mm Hg × mL, P = 0.016), leading to a more consistent pressure-volume area reduction (Impella reduction 34.7% vs PA cannula reduction 9.7%) In terms of end organ perfusion, central and mixed O<sub>2</sub> saturation improved with V-A ECLS, and subsequently, remaining unchanged with either Impella or PA cannula as unloading strategy (SVmO2: Impella 86.0 ± 5.8 vs 87.8 ± 5.8; PA cannula 82.5 ± 10.7 vs 82.5 ± 11.3 %). Transaortic suction and PA drainage provided effective LV unloading during V-A ECLS while maintaining adequate end-organ perfusion. Impella provides a greater LV unloading effect and reduces more effectively the total LV stroke work.
DOI: 10.5281/zenodo.4633122
title: Raw Data for the article: Mortality Predictors in Elderly Patients With Cardiogenic Shock on Venoarterial Extracorporeal Life Support. Analysis From the Extracorporeal Life Support Organization Registry

description: <strong>Objectives: </strong>Because significantly higher mortality is observed in elderly patients undergoing venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock, decision-making in this setting is challenging. We aimed to elucidate predictors of unfavorable outcomes in these elderly (≥ 70 yr) patients. <strong>Design: </strong>Analysis of international worldwide extracorporeal life support organization registry. <strong>Setting: </strong>Refractory cardiogenic shock due to various etiologies (cardiac arrest excluded). <strong>Patients: </strong>Elderly patients (≥ 70 yr). <strong>Interventions: </strong>Venoarterial extracorporeal membrane oxygenation. <strong>Measurements and main results: </strong>Three age groups (70-74, 75-79, ≥80 yr) were in-depth analyzed. Uni- and multivariable analysis were performed. From January 1997 to December 2018, 2,644 patients greater than or equal to 70 years (1,395 [52.8%] 70-74 yr old, 858 [32.5%] 75-79 yr, and 391 [14.8%] ≥ 80 yr old) were submitted to venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock with marked increase in the most recent years. Peripheral access was applied in majority of patients. Median extracorporeal membrane oxygenation support duration was 3.5 days (interquartile range: 1.6-6.1 d), (3.9 d [3.7-4.6 d] in patients ≥ 80 yr) (p &lt; 0.001). Weaning from extracorporeal membrane oxygenation was possible in 1,236 patients (46.7%). Overall in-hospital mortality was estimated at 68.3% with highest crude mortality rates observed in 75-79 years old subgroup (70.1%). Complications were mostly cardiovascular and bleeding, without apparent differences between subgroups. Airway pressures, 24-hour pH after extracorporeal membrane oxygenation start, extracorporeal membrane oxygenation duration, and renal replacement therapy were predictive of higher mortality. In-hospital mortality was lower in heart transplantation recipients, posttranscatheter aortic valve replacement, and pulmonary embolism; conversely, higher mortality followed extracorporeal membrane oxygenation institution after coronary artery bypass + valve and in decompensated chronic heart failure, and nearly 100% mortality followed in extracorporeal membrane oxygenation for sepsis. <strong>Conclusions: </strong>This study confirmed the remarkable increase of venoarterial extracorporeal membrane oxygenation use in elderly affected by refractory cardiogenic shock. Despite in-hospital mortality remains high, venoarterial extracorporeal membrane oxygenation should still be considered in such setting even in elderly patients, since increasing age itself was not linked to increased mortality, whereas several predictors may guide indication and management.
DOI: 10.5281/zenodo.4633387
title: Raw Data for the article: Impact of Extended-Criteria Donor Liver Grafts on Benchmark Metrics of Clinical Outcome After Liver Transplantation: A Single Center Experience

description: <strong>Background: </strong>The adoption of extended criteria for donors remains the best strategy to widen the pool of available liver graft against the chronic shortage of donors. Benchmarking in liver transplantation (LT) offers the unprecedented opportunity to compare clinical outcome measures to a set of validated reference values. We aimed to evaluate the impact of marginal grafts usage in a cohort of low-risk benchmark cases from an area with a very low rate of deceased donation. <strong>Methods: </strong>A cohort of low-risk benchmark cases was identified from all adult patients who underwent LT at our center. Among these patients, those transplanted with a graft from an extended-criteria donor (ECD) were identified. Benchmark metrics (length of hospital and intensive care unit stay, incidences of mortality, graft loss, and postoperative complication) were compared with benchmark cutoffs and between the 2 groups. <strong>Results: </strong>Two hundred forty-five patients satisfied the inclusion criteria, 146 (60%) of whom received an organ from an ECD. Overall, all benchmark metrics where within the cutoffs limits, except for graft loss (14% vs 11%) and mortality (10% vs 9% 1 year after LT). The ECD group was associated with more grade III complications (60% vs 45%, P = .031), graft loss (18% vs 8%, P = .038), and mortality (14% vs 4%, P = .009). Hepatocellular carcinoma diagnosis was found to be associated with less mortality (odds ratio = 0.42, P = .048). <strong>Conclusion: </strong>While ECD graft usage is associated with slightly worse prognosis, our experience suggests that their use can be considered safe, especially when matched on hepatocellular carcinoma recipients.